Serinus Biosciences is redefining precision in cancer therapeutics. We design models to determine how molecules function inside each tumor cell. Through our knowledge-primed AI engine, we integrate computational biology and functional genomics to uncover the molecular landscape of treatment response or resistance. Our technology enables the development of drugs that work across a wide range of patient populations, override resistance mechanisms, and enable combinations by design.

Founded by MIT PhDs and supported by Y-Combinator, Serinus is a seed-stage TechBio company backed by top investors. Serinus’s scientific advisory includes top academics from the Broad Institute, Dana-Farber, and UCSD. Join our core founding team to help us shape the company’s vision, strategy, and technology.